Cipher announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN

Mississauga, Ontario

- Cipher Pharmaceuticals announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Limited for Ranbaxy to market, sell and distribute CIP-ISOTRETINOIN in the United States, MarketWatch reports.

Under the terms of agreement, Cipher received an initial upfront milestone payment of $1 million. Pre-and post- commercialization milestone payments of up to $23 million are also part of the agreement.